Search the Newsreel

Gain Therapeutics (GANX) faces going-concern risk while advancing Parkinson’s drug

Gain Therapeutics, Inc. Q2 2026: Net loss $4.7M, EPS $(0.11) — 10-Q Summary

Gain Therapeutics, Inc. reported a net loss of $4.7M for Q2 2026, an improvement from $5.8M in the prior year, with diluted EPS at $(0.11) compared to $(0.19) in Q2 2025. The company remains pre-revenue, but advanced its clinical pipeline with an FDA-authorized IND …

Gain Therapeutics (NASDAQ:GANX) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Gain Therapeutics (NASDAQ:GANX) announced its quarterly earnings, reporting a loss of $0.11 per share, which surpassed the consensus estimate of a $0.14 loss by $0.03. Following the announcement, the company's shares increased to $1.92, contributing to its $81.76 million market capitalization. Analysts maintain a …

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

Gain Therapeutics (Nasdaq: GANX) announced its Q2 2026 financial results and a corporate update, highlighting FDA authorization of its IND for rexaceract, paving the way for Phase 2 clinical development for Parkinson's disease. The company reported continued positive results from its Phase 1b study, …

Gain Therapeutics Inc (GANX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Gain Therapeutics Inc (GANX), highlighting its current earnings forecast score of 8.80, ranking 54th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $7.00, with a consensus of "Buy" based on …

Gain Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Gain Therapeutics Inc (GANX) is projected to report a loss of 14 cents per share. This information comes from a Reuters earnings preview available on TradingView News.

Gain Therapeutics Inc (GANX) Stock News Today

This page provides current news and financial data for Gain Therapeutics Inc (GANX). As of August 7th, the stock closed at $1.82, up 2.25%, with an after-hours price of $1.78 on August 10th. The platform indicates that more news will be coming soon for …

Gain Therapeutics (GANX) Expected to Announce Quarterly Earnings on Tuesday

Gain Therapeutics Inc (GANX) Financial Health: Profitability & Balance Sheet Analysis

Gain Therapeutics Inc (GANX) currently holds a financial score of 6.75, placing it 216th out of 384 companies in the Biotechnology & Medical Research industry. The company's financial status is noted as robust despite low operational efficiency. Key financial data for profitability, operational efficiency, …

Gain Therapeutics, Inc. Revenue Breakdown – NASDAQ:GANX

This article provides a link to view the revenue breakdown for Gain Therapeutics, Inc. (NASDAQ:GANX) on TradingView. It indicates that the market is currently closed and no trades have occurred. The page offers various financial aspects, including segment and regional performance data, through its …

Gain Therapeutics Inc (GANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Gain Therapeutics Inc (GANX), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 4.91 and is trading between a resistance level of …

Gain Therapeutics Inc (GANX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Gain Therapeutics Inc (GANX), noting its current valuation score of 6.01, ranking 364 out of 386 in its industry. The company's P/E ratio is reported at -3.17, with other key metrics like P/B, P/S, and P/CF not …

Gain Therapeutics Inc (GANX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Gain Therapeutics Inc (GANX), outlining major individual and institutional holders as well as shareholder types. It provides a breakdown of institutional holdings over several quarters, showing changes in the number of institutions and shares held. Key shareholders …

Gain Therapeutics Inc (GANX) Institutional Confidence

Gain Therapeutics Inc (GANX) has an institutional shareholding score of 3.00, placing it 192nd in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 20.25%, a 58.16% increase quarter-over-quarter. Bill Nygren | OAKMX is the largest institutional shareholder with 621.47K shares, …

Gain Therapeutics Inc GANX Cash Flow Statement

This article provides the quarterly and annual cash flow statements for Gain Therapeutics Inc (GANX), allowing users to assess its financial health and stability. It details operating, investing, and financing cash flows, including net income from continuing operations, capital expenditures, and debt issuance/repayment figures. …

GANX|Gain Therapeutics Inc|Price:1.820|Chg%:+0.070

Gain Therapeutics Inc. (GANX) shows strong fundamentals and high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. Analysts maintain a "Buy" rating with a target price of $7.20, presenting a significant upside. The company specializes in developing …

Form 4 Gain Therapeutics Inc For: 17 July By Investing.com

This article reports on a Form 4 filing for Gain Therapeutics Inc (GANX) on July 17. Form 4s disclose changes in beneficial ownership of company stock by insiders. The article indicates a 3.01% gain for GANX on this date.

[Form 4] Gain Therapeutics, Inc. Insider Trading Activity

Gain Therapeutics, Inc. reported insider trading activity via a Form 4 filing, indicating that director Gwen A. Melincoff received a grant of stock options for 25,000 shares of common stock. The options were granted on July 15, 2026, with an exercise price of $1.68 …

Gain Therapeutics (GANX) awards director 25,000 stock options

Gain Therapeutics (GANX) director Claude Nicaise was granted 25,000 stock options with an exercise price of $1.68 per share, expiring on July 15, 2036. The options will vest in 12 equal monthly installments starting July 24, 2026, contingent upon his continuous service. This transaction …

Gain Therapeutics Names Joanne Taylor Chief Scientific Officer, Terenzio Ignoni as COO

Gain Therapeutics (NASDAQ: GANX) has announced the appointment of Joanne Taylor as Chief Scientific Officer and Terenzio Ignoni as Chief Operating Officer. These strategic hires aim to strengthen the company's leadership as it advances its discovery pipeline, particularly in CNS disease programs.

Gain Therapeutics advances Parkinson's drug rexaceract with positive Phase 1b data and plans Phase 2 start in Q3 2026

Gain Therapeutics announced positive Phase 1b clinical trial results for its Parkinson's drug candidate, rexaceract, demonstrating safety, tolerability, and initial signs of efficacy. The FDA has approved its Investigational New Drug application, allowing the company to proceed with a Phase 2 study in Q3 …

Gain Therapeutics says cash runway extends into Q2 2027 amid Phase 2 start plans

Gain Therapeutics (GANX) announced that its current cash and cash equivalents are projected to fund operations into the second quarter of 2027. This financial outlook is based on existing operating plans, including the completion of a Phase 1b open-label extension in October 2026 and …

Gain Therapeutics (NASDAQ: GANX) sees cash funding into Q2 2027

Gain Therapeutics (NASDAQ: GANX) announced that its current cash and cash equivalents are expected to fund operations into the second quarter of 2027 based on its current operating plans. This cash runway supports the completion of a Phase 1b open-label extension in October 2026 …

Gain Therapeutics plans phase 2 Parkinson’s study in Q3 2026 By Investing.com

Gain Therapeutics (NASDAQ:GANX) announced it received FDA authorization to begin a Phase 2 clinical study for rexaceract, its Parkinson’s disease treatment, in Q3 2026. The company reported positive results from its ongoing Phase 1b extension study, with all participants continuing treatment and an average …

Gain Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss but Shares Decline - Analyst Drop Coverage

FDA clears Gain Therapeutics drug GT-02287 for Phase 2 Parkinson’s trial

Gain Therapeutics, Inc. Actuals & Estimates (NASDAQ:GANX)

GANX Forecast — Price Target — Prediction for 2027

Gain Therapeutics (GANX) Upgraded to Buy: Here's Why

Gain Therapeutics Sees Stock Surge Amid Positive Clinical Results and Ambitious Price Target Increase

Gain Therapeutics, Inc. Share Price Live Today – NASDAQ:GANX Stock Price, Chart, News, History

Gain Therapeutics (GANX) Stock Price, News & Analysis

Gain Therapeutics Inc (GANX) News, Articles, Events & Latest Updates